Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas | Regeneron Pharmaceuticals Inc.

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas May 18, 2026 at 7:00 AM EDT PDF Version The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron , consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y. , May 18, 2026 (GLOBE NEWSWI

related reading

• News — Pacific 8 Venturespac8.com
• Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
• The 23andMe Deal - Cremieux Recueilcremieux.xyz
• Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides | Nature Communicationsnature.com
• Mesa — JURA Bio, Inc.jura.bio
• Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
• Neion Bioneionbio.com
• Dyno Therapeutics: The Capsids You Needcenturyofbio.com
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• Early-Stage Biotech Value Creation: The Roles of Equity and Partnershipsleadershipandbiotechnology.blogspot.com
• Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
• NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trialsblog.newlimit.com